Antiglycation activity of triazole Schiff's bases against fructose-mediated glycation: In vitro and in silico study.

Clicks: 362
ID: 100186
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #12 of 111 articles by views in medicinal chemistry (shariqah (united arab emirates))

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Advanced glycation end products (AGEs) are known to be involved in pathophysiology of diabetic complications, neurodegenerative diseases, and aging. Preventing the formation of AGEs can be helpful in the management of these diseases.Two classes of previously synthesized traizole Schiff's bases (4H-1,2,4-triazole-4-Schiff's bases 1-14, and 4H-1,2,4-triazole-3-Schiff's bases 15-23) were evaluated for their in vitro antiglyaction activity.In vitro fructose-mediated human serum albumin (HSA) glycation assay was employed to assess the antiglycation activity of triazole Schiff's bases. The active compounds were subjected to cytotoxicity analysis by MTT assay on mouse fibroblast (3T3) cell line. Molecular docking and simulation studies were carried out to find out the interactions and stability of compounds with HSA. Antiglycemic and antioxidant potential of active, and non-cytotoxic compounds were evaluated by in vitro α-glucosidase inhibition assay, and DPPH free radical scavenging assay, respectively.Compound 1 (IC50 = 47.30 ± 0.38 µM) from 4H-1,2,4-triazole-4-Schiff's bases exhibited antiglycation activity comparable to standard rutin (IC50 = 54.5 ± 0.05 µM) along with stable RMSD profile in MD simulation studies. Compound 1 also exhibited potent α-glucosidase inhibitory activity and moderate antioxidant property. Other derivatives showed a weak antiglycation activity with IC50 values between 248.1 - 637.7 µM. Compounds with potential antiglycation profile were found to the formation of be non-cytotoxic in cellular assay.The study identifies triazole Schiff's bases active against fructose-mediated glycation of HSA, thus indicates their potential against late diabetic complications due to advanced glycation end products (AGEs).
Reference Key
shaikh2019antiglycationmedicinal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shaikh, Muniza;Siddiqui, Salman;Zafar, Humaira;Naqeeb, Uzma;Subzwari, Fakiha;Imad, Rehan;Khan, Khalid Mohammed;Choudhary, M Iqbal;
Journal medicinal chemistry (shariqah (united arab emirates))
Year 2019
DOI
10.2174/1573406415666190212105718
URL
Keywords
Rutin fructose antiglycation human serum albumin triazole schiff’s bases

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.